Aerovate Therapeutics, Inc. (AVTE)
NASDAQ: AVTE · Real-Time Price · USD
2.790
+0.340 (13.88%)
At close: Nov 1, 2024, 4:00 PM
2.731
-0.059 (-2.11%)
After-hours: Nov 1, 2024, 7:02 PM EDT

Aerovate Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Net Income
-87.94-75.52-51.51-22.96-9.61-3.33
Depreciation & Amortization
0.110.10.070.020-
Loss (Gain) From Sale of Investments
-3.2-3.06-0.910.02--
Stock-Based Compensation
14.5511.915.482.040.06-
Other Operating Activities
----0.72-
Change in Accounts Payable
-1.28-0.161.370.610.040.44
Change in Other Net Operating Assets
3.239.966.39-7.120.940.11
Operating Cash Flow
-74.52-56.78-39.12-27.4-7.86-2.78
Capital Expenditures
-0.1-0.14-0.2-0.18--
Investment in Securities
19.4512.027.12-113.25--
Investing Cash Flow
19.3511.886.93-113.43--
Short-Term Debt Issued
----2.52.5
Total Debt Issued
----2.52.5
Net Debt Issued (Repaid)
----2.52.5
Issuance of Common Stock
25.7246.230.77126.950.01-
Other Financing Activities
-0.38-0.23-0.37---
Financing Cash Flow
25.33460.4190.468.922.5
Net Cash Flow
-29.831.09-31.849.621.06-0.28
Free Cash Flow
-74.61-56.92-39.32-27.58-7.86-2.78
Free Cash Flow Per Share
-2.65-2.16-1.61-2.24-32.44-11.52
Levered Free Cash Flow
-44.86-28.72-18.2-18.78-4.53-
Unlevered Free Cash Flow
-44.86-28.72-18.2-18.78-4.48-
Change in Net Working Capital
0.54-10.3-9.726.27-1.01-
Source: S&P Capital IQ. Standard template. Financial Sources.